Correction to: Rare Adverse Events with Programmed Death-1 and Programmed Death-Ligand 1 Inhibitors: Justification and Rationale for a Systematic Review (Current Oncology Reports, (2021), 23, 8, (86), 10.1007/s11912-021-01089-9)

Caleb J. Smith, Yahya Almodallal, Aminah Jatoi

Research output: Contribution to journalComment/debatepeer-review

Abstract

The original version of this article unfortunately contained a mistake in the article title. It should read “Programmed Death-Ligand 1 Inhibitors,” not “Programmed Death-1 Ligand Inhibitors”. The original article has been corrected.

Original languageEnglish (US)
Article number98
JournalCurrent oncology reports
Volume23
Issue number8
DOIs
StatePublished - Aug 2021

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Correction to: Rare Adverse Events with Programmed Death-1 and Programmed Death-Ligand 1 Inhibitors: Justification and Rationale for a Systematic Review (Current Oncology Reports, (2021), 23, 8, (86), 10.1007/s11912-021-01089-9)'. Together they form a unique fingerprint.

Cite this